Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: Relationship between compliance with the guidelines and prevention of CMV morbidity

Transplant Infectious Disease

Volumn 2, Issue 3, 2000, Pages 118-126

  Kunzle N ^a   Petignat, C ^a   Francioli, P ^a   Vogel, G ^a   Seydoux, C ^a   Corpataux, J M ^a   Sahli, R ^a   Meylan, P R A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cytomegalovirus; Ganciclovir; Preemptive treatment; Quantitative culture; Solid organ transplant

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MORBIDITY; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; TIME FACTORS; VIREMIA;

EID: 0033811170     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2000.020304.x     Document Type: Article

References (33)

1. Cytomegalovirus pneumonitis after cardiac transplantation
2. Cytomegalovirus disease in renal allograft recipients: A prospective study of the clinical features, risk factors and impact on renal transplantation
3. Cytomegalovirus infection and disease in renal transplant patients treated with cyclosporin
4. Cytomegalovirus infection following liver transplantation: Review of the literature
5. Cytomegalovirus
6. Cytomegalovirus prophylaxis in solid organ transplant recipients
7. Prevention of cytomegalovirus disease in transplant recipients
8. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia
9. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
10. Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection
11. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation
12. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients
13. Cytomegalovirus infection and disease in solid organ transplant recipients
14. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
15. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis transplantation Study Group
16. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients
17. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy
18. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications
19. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
20. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
21. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy
22. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: Examination of a preemptive plan of ganciclovir therapy
23. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants
24. Preemptive treatment for the prevention of cytomegalovirus disease in lung and heart transplant recipients
25. Quantitative analysis of cytomegalovirus viremia in lung transplant recipients
26. Comparison of PCR and pp65 antigenemia assay with quantitative shell vial culture for detection of cytomegalovirus in blood leukocytes from solid-organ transplant recipients
27. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen
28. Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins
29. Definitions of cytomegalovirus infection and disease
30. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: Importance of cytomegalovirus viremia
31. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients
32. Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients
33. Single tube competitive PCR for quantitation of CMV DNA in the blood of HIV+ and solid organ transplant patients